The board of trustees (the "Board") of NXG Cushing® Midstream Energy Fund (the "Fund") has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

Established to produce biosimilars against AbbVie’s (ABBV) Humira in partnership with Sandoz (OTCQX:SDZNY) and Boehringer Ingelheim, Cordavis, and Quallent illustrated PBM’s latest attempts to ...